UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called “bubble boy” disease, a life-threatening condition that if left untreated can be fatal within one to two years.
In the 11-year study, researchers were able to test two therapy regimens for 10 children with ADA-deficient severe combined immunodeficiency (SCID), which has come to be known as “bubble boy” disease because some of its victims have been forced to live in sterile environments. (more…)
Drug efficiently targets breast, lung and colon cancer; clinical trials could start within two years.
COLUMBIA, Mo. — Legend has it that Ralph Waldo Emerson once said, “Build a better mousetrap, and the world will beat a path to your door.” University of Missouri researchers are doing just that, but instead of building mousetraps, the scientists are targeting cancer drugs. In a new study, MU medicinal chemists have taken an existing drug that is being developed for use in fighting certain types of cancer, added a special structure to it, and created a more potent, efficient weapon against cancer.
“Over the past decade, we have seen an increasing interest in using carboranes in drug design,” said Mark W. Lee Jr., assistant professor of chemistry in College of Arts and Science. “Carboranes are clusters of three elements — boron, carbon and hydrogen. Carboranes don’t fight cancer directly, but they aid in the ability of a drug to bind more tightly to its target, creating a more potent mechanism for destroying the cancer cells.” (more…)
In new study published in PNAS, scientists found that nanoparticles, produced from chemicals in tea, reduced tumors by 80 percent.
COLUMBIA, Mo. – Currently, large doses of chemotherapy are required when treating certain forms of cancer, resulting in toxic side effects. The chemicals enter the body and work to destroy or shrink the tumor, but also harm vital organs and drastically affect bodily functions. Now, University of Missouri scientists have found a more efficient way of targeting prostate tumors by using gold nanoparticles and a compound found in tea leaves. This new treatment would require doses that are thousands of times smaller than chemotherapy and do not travel through the body inflicting damage to healthy areas. The study is being published in the Proceedings of the National Academy of Science. (more…)
COLUMBUS, Ohio – Blocking a protein in the heart that is produced under stressful conditions could be a strategy to prevent cardiac damage that results from chemotherapy, a new study suggests.
Previous research has suggested that up to a quarter of patients who receive the common chemotherapy drug doxorubicin are at risk of developing heart failure later in life. Exactly how that heart damage is done remains unclear.
In this study, scientists identified a protein called heat shock factor-1 (HSF-1) as a likely source of chemotherapy-related heart damage in mice and cell cultures. Heat shock factor-1 is known to be induced by stress – in this case, the chemotherapy treatment itself. (more…)
Breast cancer stem cells, thought to be the sole source of tumor recurrence, are known to be resistant to radiation therapy and don’t respond well to chemotherapy.
Now, researchers with the UCLA Department of Radiation Oncology at UCLA’s Jonsson Comprehensive Cancer Center report for the first time that radiation treatment, despite killing half of all tumor cells during every treatment, transforms other cancer cells into treatment-resistant breast cancer stem cells.(more…)
Suppressing a newly identified protein involved in regulating cell division could be a novel strategy for fighting certain cancers because it stops the malignant cells from dividing and causes them to die quickly, according to a study by researchers at UCLA’s Jonsson Comprehensive Cancer Center.
During the five-year study, designed to seek new targets for anti-cancer therapies, researchers discovered that depleting the protein, called STARD9, also helped the commonly used chemotherapy drug Taxol work more effectively against certain cancers. (more…)
Sara Rockwell is a leader in her field. A professor of therapeutic radiology and pharmacology at the School of Medicine, Rockwell was among the first researchers to study the effects of oxygen deficiency on the response of malignant cells to radiation and anticancer drugs, and was among the first to consider the implications of this deficiency in microscopic tumors for the development of solid malignancies.
Rockwell, who is also associate dean for scientific affairs, joined the faculty of Yale School of Medicine in 1974, and teaches radiation biology, pharmacology, cancer biology, ethics and career development skills. She earned her bachelor’s degree in physics from Penn State University in 1965. She went on to earn her doctorate degree in biophysics from Stanford University in 1971. (more…)
COLUMBIA, Mo. – For some women, the effects of breast cancer, the most common cancer affecting women, do not end when they leave the hospital. Now, researchers in the University of Missouri School of Health Professions have studied the lives of breast cancer patients following chemotherapy and found that their environments and available support systems help determine the quality of their lives.
“A lot of times people get mentally and emotionally ready to deal with chemotherapy and they receive a lot of support during that time,” said Stephanie Reid-Arndt, an assistant professor of health psychology in the School of Health Professions. “Then they go home and everyone feels like it’s over, but the patients still have worries and fears about the changes they’ve been through and what it means for the future.” (more…)
